Welcome to
KaNDy
Therapeutics
Therapeutics
Developing a breakthrough non-hormonal treatment for multiple symptoms of the menopause including hot flashes and waking due to night sweats
A unique approach
Progressing our unique once daily dual mechanism neurokinin antagonist, NT-814, as a potential breakthrough treatment for multiple symptoms of the menopause. Following a successful Phase 2a proof of concept study, NT-814 completed a Phase 2b study, SWITCH-1, with data reported in January 2020. The study demonstrated NT-814’s potential to rapidly and profoundly reduce key symptoms of the menopause. SWITCH-1 found that NT-814 significantly reduced the frequency of hot flashes, which was associated with improvements in quality of life, mood and sleep.
Latest News
Contact Us
For general, media or partnership enquiries, get in touch with us:
